Snakebites Injury, Occupational Diseases, Poisoning Snakebites
Conditions
Interventions
After snakebite envenoming diagnosis, participants are randomly assigned to one of two arms with allocation ratio 1:1. The randomisation list is computer-generated. When a patient is considered to mee
Sponsors
Army Institute of Biology
Tropical Medicine Foundation Dr. Heitor Vieira Dourado
Instituto de Biologia do Exército
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female subjects 2. Aged between 12 and 70 years old 3. Bothrops, Lachesis and Crotalus snakebites are diagnosed using clinical, epidemiological and laboratorial evaluation
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding 2. Previous hematological disorders 3. Known immunodeficiencies (HIV, malignancies, chemotherapy or other immunosuppressive treatments) 4. Previous treatment with snake AVs and history of any moderate/severe allergic reaction in the past 5. Presenting with severe snake envenomings, defined for Bothrops and Lachesis as life-threatening snakebites with severe bleeding, hypotension, shock and acute renal failure, and for Crotalus as intense rhabdomyolisis and severe acute renal failure were not included
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early adverse reactions of AV therapy is measured using the clinical examinations for urticaria, asthma-like crisis, laryngeal edema and shock in the first 24 hours after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of late adverse events are measured using clinical examinations (fever, urticarial, arthralgia, adenomegaly, neurological and renal complications at 24 hours until 15 days after treatment. | — |
Countries
Brazil
Outcome results
None listed